{
    "2018-06-27": [
        [
            {
                "time": "",
                "original_text": "医药健康行业周报：百时美施贵宝PD-1单抗OPDIVO获批生产点评",
                "features": {
                    "keywords": [
                        "医药健康",
                        "百时美施贵宝",
                        "PD-1单抗",
                        "OPDIVO",
                        "获批生产"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "[推荐评级] 医药行业周报：什么是股市波动中的避风港 - 安全性+确定性板块",
                "features": {
                    "keywords": [
                        "医药行业",
                        "推荐评级",
                        "避风港",
                        "安全性",
                        "确定性"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}